BG63363B1 - Използване на антагонист на gnrh за получаване нафармацевтичен състав за лечение на гонадостероидно зависими заболявания - Google Patents

Използване на антагонист на gnrh за получаване нафармацевтичен състав за лечение на гонадостероидно зависими заболявания Download PDF

Info

Publication number
BG63363B1
BG63363B1 BG101158A BG10115897A BG63363B1 BG 63363 B1 BG63363 B1 BG 63363B1 BG 101158 A BG101158 A BG 101158A BG 10115897 A BG10115897 A BG 10115897A BG 63363 B1 BG63363 B1 BG 63363B1
Authority
BG
Bulgaria
Prior art keywords
estrogen
antagonist
dose
progesterone
use according
Prior art date
Application number
BG101158A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG101158A (en
Inventor
Gary HODGEN
Audrey Philips
Original Assignee
The Medical College Of Hampton Roads
Ortho Pharmaceutical Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26959766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG63363(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/467,860 external-priority patent/US5658884A/en
Application filed by The Medical College Of Hampton Roads, Ortho Pharmaceutical Corporation filed Critical The Medical College Of Hampton Roads
Publication of BG101158A publication Critical patent/BG101158A/xx
Publication of BG63363B1 publication Critical patent/BG63363B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BG101158A 1994-07-22 1997-01-21 Използване на антагонист на gnrh за получаване нафармацевтичен състав за лечение на гонадостероидно зависими заболявания BG63363B1 (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27959394A 1994-07-22 1994-07-22
US08/467,860 US5658884A (en) 1994-07-22 1995-06-06 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
PCT/US1995/008996 WO1996003138A1 (en) 1994-07-22 1995-07-18 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens

Publications (2)

Publication Number Publication Date
BG101158A BG101158A (en) 1997-09-30
BG63363B1 true BG63363B1 (bg) 2001-11-30

Family

ID=26959766

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101158A BG63363B1 (bg) 1994-07-22 1997-01-21 Използване на антагонист на gnrh за получаване нафармацевтичен състав за лечение на гонадостероидно зависими заболявания

Country Status (29)

Country Link
EP (1) EP0769956B1 (sv)
JP (1) JP3138477B2 (sv)
CN (1) CN1137722C (sv)
AP (1) AP775A (sv)
AT (1) ATE190494T1 (sv)
AU (1) AU691952B2 (sv)
BG (1) BG63363B1 (sv)
BR (1) BR9508718A (sv)
CA (1) CA2195745C (sv)
CY (1) CY2228B1 (sv)
CZ (1) CZ291803B6 (sv)
DE (1) DE69515666T2 (sv)
DK (1) DK0769956T3 (sv)
EE (1) EE03515B1 (sv)
ES (1) ES2145286T3 (sv)
FI (1) FI970244A (sv)
GR (1) GR3033590T3 (sv)
HU (1) HU218910B (sv)
IL (1) IL114655A (sv)
IS (1) IS4413A (sv)
LV (1) LV11823B (sv)
MX (1) MX9700574A (sv)
NO (1) NO970257L (sv)
NZ (1) NZ290554A (sv)
OA (1) OA10730A (sv)
PT (1) PT769956E (sv)
RU (1) RU2181598C2 (sv)
SK (1) SK282118B6 (sv)
WO (1) WO1996003138A1 (sv)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173592B1 (en) 1999-03-31 2012-05-08 Zentaris Ivf Gmbh Method for a programmed controlled ovarian stimulation protocol
NZ534836A (en) * 1999-09-23 2007-07-27 Zentaris Gmbh Method for the therapeutic management of extrauterine proliferatoin of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
GB0616111D0 (en) * 2006-06-16 2006-09-20 Ardana Bioscience Ltd Agents, methods and uses
EP2095818A1 (en) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
US20110129532A1 (en) * 2008-05-29 2011-06-02 Isr Immune System Regulation Ab Method and means for treating viral disease, in particular hiv/aids
WO2016184829A1 (en) * 2015-05-18 2016-11-24 Nerre Therapeutics Limited Dual nk-1/nk-3 receptor antagonists for the treatment of sex-hormone-dependent diseases
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171835A (en) * 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
US5169932A (en) * 1989-10-30 1992-12-08 The Salk Institute For Biological Studies Gnrh analogs
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease

Also Published As

Publication number Publication date
JP3138477B2 (ja) 2001-02-26
AP9700913A0 (en) 1997-01-31
ATE190494T1 (de) 2000-04-15
IL114655A (en) 2005-08-31
DK0769956T3 (da) 2000-06-05
JPH10503203A (ja) 1998-03-24
OA10730A (en) 2001-06-07
AP775A (en) 1999-10-28
EE9700208A (et) 1998-02-16
CY2228B1 (en) 2003-04-18
FI970244A0 (sv) 1997-01-21
ES2145286T3 (es) 2000-07-01
HU218910B (hu) 2000-12-28
EP0769956B1 (en) 2000-03-15
NZ290554A (en) 2000-08-25
RU2181598C2 (ru) 2002-04-27
WO1996003138A1 (en) 1996-02-08
NO970257D0 (no) 1997-01-21
IL114655A0 (en) 1995-11-27
LV11823A (lv) 1997-08-20
EE03515B1 (et) 2001-10-15
PT769956E (pt) 2000-07-31
CN1200674A (zh) 1998-12-02
CZ291803B6 (cs) 2003-06-18
DE69515666T2 (de) 2000-07-06
IS4413A (is) 1997-01-14
HUT77127A (hu) 1998-03-02
CZ15097A3 (en) 1997-11-12
HU9700046D0 (en) 1997-02-28
SK7097A3 (en) 1997-11-05
EP0769956A4 (en) 1999-03-10
GR3033590T3 (en) 2000-09-29
AU3132095A (en) 1996-02-22
BG101158A (en) 1997-09-30
NO970257L (no) 1997-01-21
EP0769956A1 (en) 1997-05-02
DE69515666D1 (de) 2000-04-20
LV11823B (en) 1998-03-20
MX9700574A (es) 1997-12-31
AU691952B2 (en) 1998-05-28
CN1137722C (zh) 2004-02-11
FI970244A (sv) 1997-01-21
CA2195745A1 (en) 1996-02-08
BR9508718A (pt) 1997-12-30
CA2195745C (en) 2005-03-29
SK282118B6 (sk) 2001-11-06

Similar Documents

Publication Publication Date Title
EP0785792B1 (en) Treatment of ovarian estrogen dependent conditions
US7309691B2 (en) Combined pharmaceutical preparation containing LHRH-analogous substances and anti estrogens for treating gynaecological disorders
WO1998058657A1 (en) Gonadotropin releasing hormone antagonist
BG63363B1 (bg) Използване на антагонист на gnrh за получаване нафармацевтичен състав за лечение на гонадостероидно зависими заболявания
US5658884A (en) Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
Taymor et al. Induction of ovulation